FLGC vs. IMMX, MGX, ADVM, GANX, SKYE, DTIL, IKNA, KPTI, RENB, and ARTV
Should you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include Immix Biopharma (IMMX), Metagenomi (MGX), Adverum Biotechnologies (ADVM), Gain Therapeutics (GANX), Skye Bioscience (SKYE), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Karyopharm Therapeutics (KPTI), Renovaro (RENB), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry.
Flora Growth vs.
Flora Growth (NASDAQ:FLGC) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 12.6% of Flora Growth shares are owned by insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Flora Growth received 4 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 60.00% of users gave Flora Growth an outperform vote.
Flora Growth has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Immix Biopharma has a net margin of 0.00% compared to Flora Growth's net margin of -30.99%. Immix Biopharma's return on equity of -102.68% beat Flora Growth's return on equity.
In the previous week, Flora Growth had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Flora Growth and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.00 beat Flora Growth's score of -0.59 indicating that Immix Biopharma is being referred to more favorably in the news media.
Immix Biopharma has lower revenue, but higher earnings than Flora Growth. Immix Biopharma is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Flora Growth currently has a consensus price target of $4.00, indicating a potential upside of 534.92%. Immix Biopharma has a consensus price target of $7.00, indicating a potential upside of 234.93%. Given Flora Growth's higher possible upside, equities research analysts plainly believe Flora Growth is more favorable than Immix Biopharma.
Summary
Flora Growth and Immix Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Flora Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flora Growth Competitors List
Related Companies and Tools
This page (NASDAQ:FLGC) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy FLGC Stock Free FLGC Stock Alerts